39 terminated, 12 completed, 9 withdrawn, 1 suspended. 60 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 60 | Terminated 39, Completed 12, Withdrawn 8, Suspended 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow antineoplaston AS 2-1: new trials by email Literature Review of antineoplaston AS 2-1 trials Research Report on antineoplaston AS 2-1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG) Antineoplaston therapy (Atengenal + Astugenal) - Diffuse, Intrinsic Pontine Glioma | Phase 2 | Suspended | Burzynski Research Institute | 1 | 2016-04-13 | 2025-09-16 |
| Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma Temozolomide, ANP Therapy - Optic Nerve Glioma | Phase 3 | Withdrawn | Burzynski Research Institute | 2011-12-01 | 2017-07-26 | |
| Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma Antineoplaston therapy (Atengenal + Astugenal) - CNS Tumor | Phase 2 | Terminated | Burzynski Research Institute | 3 | 1999-03-01 | 2017-07-26 |
| Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia Antineoplaston therapy (Atengenal + Astugenal) - Waldenstrom Macroglobulinemia | Phase 2 | Withdrawn | Burzynski Research Institute | 1999-02-18 | 2018-02-05 | |
| Antineoplaston Therapy in Treating Patients With Meningioma Antineoplaston therapy (Atengenal + Astugenal) - Meningioma | Phase 2 | Terminated | Burzynski Research Institute | 3 | 1998-06-01 | 2017-08-24 |
| Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma Antineoplaston therapy (Atengenal + Astugenal) - Non Hodgkin Lymphoma | Phase 2 | Terminated | Burzynski Research Institute | 5 | 1997-10-13 | 2021-01-22 |
| Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine Antineoplaston therapy (Atengenal + Astugenal) - Small Intestine Cancer | Phase 2 | Terminated | Burzynski Research Institute | 1 | 1997-08-13 | 2017-09-29 |
| Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma Antineoplaston therapy (Atengenal + Astugenal) - Neuroblastoma | Phase 2 | Terminated | Burzynski Research Institute | 3 | 1996-12-16 | 2017-09-28 |
| Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors Antineoplaston therapy (Atengenal + Astugenal) - Primitive Neuroectodermal Tumor | Phase 2 | Terminated | Burzynski Research Institute | 1 | 1996-12-12 | 2017-09-29 |
| Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer Antineoplaston therapy (Atengenal + Astugenal) - Stage IV Prostate Cancer | Phase 2 | Withdrawn | Burzynski Research Institute | 1996-10-11 | 2018-01-31 | |
| Antineoplaston Therapy in Treating Patients With Stomach Cancer Antineoplaston therapy (Atengenal + Astugenal) - Stomach (Gastric) Cancer | Phase 2 | Terminated | Burzynski Research Institute | 1 | 1996-10-04 | 2017-09-29 |
| Antineoplaston Therapy in Treating Children With Brain Tumors Antineoplaston therapy (Atengenal + Astugenal) - Childhood Brain Tumors | Phase 2 | Completed | Burzynski Research Institute | 34 | 1996-09-01 | 2022-03-07 |
| Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Antineoplaston therapy (Atengenal + Astugenal) - Stage IV Adrenocortical Carcinoma | Phase 2 | Terminated | Burzynski Research Institute | 6 | 1996-08-21 | 2018-05-09 |
| Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer Antineoplaston therapy (Atengenal + Astugenal) - Stage IV Non-small Cell Lung Cancer | Phase 2 | Terminated | Burzynski Research Institute | 9 | 1996-08-21 | 2018-02-05 |
| Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma Antineoplaston therapy (Atengenal + Astugenal) - Low Grade Astrocytomas | Phase 2 | Completed | Burzynski Research Institute | 11 | 1996-07-01 | 2023-11-21 |
| Antineoplaston Therapy in Treating Patients With Brain Tumors Antineoplaston therapy (Atengenal + Astugenal) - Refractory Brain Tumors | Phase 2 | Completed | Burzynski Research Institute | 40 | 1996-07-01 | 2017-08-22 |
| Antineoplaston Therapy in Treating Patients With Soft Tissue Sarcoma Antineoplaston therapy (Atengenal + Astugenal) - Soft Tissue Sarcoma | Phase 2 | Terminated | Burzynski Research Institute | 14 | 1996-06-14 | 2017-09-29 |
| Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva Antineoplaston therapy (Atengenal + Astugenal) - Cervical Cancer Stage IV, Vulvar Cancer, Stage IV | Phase 2 | Terminated | Burzynski Research Institute | 8 | 1996-06-03 | 2017-09-29 |
| Antineoplaston Therapy in Treating Children With Visual Pathway Glioma Antineoplaston therapy (Atengenal + Astugenal) - Visual Pathway Glioma | Phase 2 | Completed | Burzynski Research Institute | 12 | 1996-06-01 | 2017-08-24 |
| Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus Antineoplaston therapy (Atengenal + Astugenal) - Adenocarcinoma of the Esophagus | Phase 2 | Terminated | Burzynski Research Institute | 8 | 1996-05-30 | 2021-05-14 |
Showing 20 of 61. Sign in to see all of them.
Astrocytoma (8) · Glioblastoma (5) · Lymphoma, Non-Hodgkin (4) · Neuroectodermal Tumors, Primitive (4) · Prostatic Neoplasms (4) · Lung Neoplasms (3) · Recurrence (3) · Brain Neoplasms (2) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Colonic Neoplasms (2) · Glioma (2) · Neoplasms (2) · Neurocytoma (2) · Oligodendroglioma (2)
Burzynski Research Institute (61)
United States (60)
Stanislaw R. Burzynski, MD, PhD (58) · Stanislaw R Burzynski, MD, PhD (3)